De fleste af patienterne fik forsøgsmedicinen i tilgift til konventionel behandling, inklusive trombocytfunktionshæmmende midler, lipidsænkende midler og betablokkere.
Most of the patients received the study medication on top of conventional therapy including platelet inhibitors, lipid lowering agents and beta-blockers.